EctoPharma signs two enabling licence deals for nano-anticancer research
This article was originally published in Scrip
Executive Summary
EctoPharma has entered into two separate licensing agreements with the UK's Medical Research Council (MRC) and University of London's School of Pharmacy concerning research into a novel nanotechnology for cancer treatment.